---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-048740"
form_type: "8-K"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2023-06-14T23:59:59+00:00"
generated_at: "2026-06-14T01:26:27.122183+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Blue Water Biotech acquires six FDA-approved drugs for $8.5M cash and 1M shares

## Summary
- Total consideration $8.5M cash (payable in three tranches) plus 1.0M restricted shares of BWV common stock.
- Assets include ZONTIVITY (PAD/MI), OTOVEL/CETRAXAL (otic), CONJUPRI (hypertension), TREZIX/NALFON (pain).
- Closing subject to delivery of audited 2022 financials of seller’s parent and other customary conditions.
- Company will manage assets during pre-closing period; Blue Water becomes commercial-stage biopharma.

## SEC filing metadata
- accession: 0001213900-23-048740
- form_type: 8-K
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2023-06-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000121390023048740/0001213900-23-048740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000121390023048740/ea180344-8k_bluewater.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-048740
- JSON: https://secwatch.observer/filing/0001213900-23-048740.json
- Plain text: https://secwatch.observer/filing/0001213900-23-048740.txt

## Key facts
- Material Agreements
  Onconetix, Inc. entered into Purchase Agreement with WraSer, LLC, Xspire Pharma, LLC, and Legacy-Xspire Holdings, LLC (effective 2023-06-13).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: WraSer, LLC, Xspire Pharma, LLC, and Legacy-Xspire Holdings, LLC
  - Effective: 2023-06-13
  source text: On June 13, 2023, Blue Water Biotech, Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) with WraSer, LLC, a Mississippi limited liability company, Xspire Pharma, LLC, a Mississippi limited liability company (collectively, the “Seller”), and Legacy-Xspire Holdings, LLC, a Delaware limited liability company and the parent company of the Seller (“Parent”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390023048740/0001213900-23-048740-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.